Chronic hepatitis B virus (HBV) infection exhibits complex host-virus interactions, leading to distinctive clinical features at different disease stages. The natural history of HBV acquired in the perinatal period or childhood can be divided into four chronological phases: immune tolerance (IT), immune clearance (IC), inactive carrier or lowreplication (LR) and reactivation or HBeAg-negative hepatitis (ENH) [1] . Liver cirrhosis and hepatocellular carcinoma (HCC) are the long-term detrimental consequences of chronic HBV infection. The risk of chronic hepatitis B (CHB) patients for the development of end-stage liver disease is as high as 40 % in the lifetime [2] . The main driving force for disease progression is the viral replication and immune-mediated hepatic necroinflammation. Current guidelines recommend that antiviral therapy should be given to patients with active viral replication, hepatic necroinflammation and significant hepatic fibrosis, primarily for those at the IC or ENH phases [3] . Therefore, precise determination of the clinical phase of a given patient is important to provide timely antiviral therapy to improve long-term outcomes.
In our clinical practice, the serum HBV DNA level, presence or absence of HBeAg, and the alanine aminotransferase (ALT) level are commonly utilized to identify the clinical phases of chronic HBV infection. However, these assays are not perfect, and the clinical phase may not be accurately determined in a small proportion of patients. For example, sometimes, the IT and IC phases cannot be correctly characterized in patients with elevation of ALT levels caused by other etiologies, such as non-alcoholic steatohepatitis (NASH) or drug-induced liver injury (DILI). Likewise, the LR and ENH phases are somewhat difficult to distinguish, particularly in those with fluctuating ALT levels and long intervening remission periods. Therefore, novel HBV serological assays are necessary to better define the clinical phases of CHB patients.
In this issue, Wang et al. [4] compared three quantitative HBV serological markers, HBsAg, HBeAg and Hepatitis B core antibody (anti-HBc) levels, as well as HBV DNA levels to differentiate the clinical phases of Chinese CHB patients. In this cross-sectional study, they found that HBsAg level gradually declined as the disease proceeds through the IT, IC and eventually LR phases, but rebounded after reactivation in ENH phase. Both HBsAg and HBeAg levels are lower in the IC phase than in the IT phase, and have a good predictive value in the differenti- Quantification assays are theoretically more informative than qualification ones. The role of HBV DNA levels in the natural history and risk of liver cirrhosis and HCC have been recognized in the community-based REVEAL-HBV cohort study in Taiwan [5, 6] . Recent studies have also shown the important role of HBsAg quantification in the natural history of CHB. HBsAg levels evolve along with the natural courses of CHB [7] . The HBsAg level is highest in the IT phase and starts to decline from the entry of the IC phase toward an LR phase, unless reactivation of HBV occurs. A previous study on the HBsAg kinetics of HBeAg-negative CHB patients showed that the HBsAg level was weakly correlated with the HBV DNA level. Significant HBsAg reduction was only observed in patients with undetectable HBV DNA [8] . Another study reported that, in an Italian cohort of 209 untreated and asymptomatic HBeAg-negative genotype D carriers, the combination of single-point quantification of HBsAg (\1000 IU/ mL) and HBV DNA (\2000 IU/mL) could more accurately identify a 3-year inactive carrier state [9] . Our previous study demonstrated that, compared to the HBV DNA level, the HBsAg level is a better predictor for HBsAg loss in spontaneous HBeAg seroconverters [10] . Consistently, a large case-control study on Chinese CHB patients also reported that serum HBsAg \ 200 IU/mL and 0.5-log reduction in HBsAg could predict HBsAg seroclearance within 3 years [11] . In addition, in patients with low viremia (\2000 IU/mL), the higher HBsAg level ([1000 IU/ mL) is associated with the risk of disease progression, including hepatitis flares, ENH, liver cirrhosis and HCC [12, 13] . In patients with low viremia (\2000 IU/mL) (Taiwanese patients with HBV genotype B or C infection), HBsAg \ 1000 IU/mL can identify a subgroup of minimal-risk HBV carriers with an annual HCC incidence of 0.06 %. Moreover, the role of quantitative HBsAg levels in the development of liver cirrhosis and HCC has been validated in the REVEAL-HBV cohort study. In addition, the new risk prediction models of cirrhosis and HCC have excellent prediction accuracy by the integration of HBsAg levels and other host and HBV profiles [14] .
Hepatitis B core antigens induce strong immune responses during HBV infection. IgG anti-HBc persists lifelong in individuals with prior exposure to HBV, even in those who have recovered from acute hepatitis B for many years. However, the characteristics of total anti-HBc levels during CHB remain unclear. A recent study showed that quantitative total anti-HBc levels were positively correlated with ALT levels in CHB patients [15] . In addition, anti-HBc levels vary at different clinical phases [16] : higher in an inflammatory state, including the IC and ENH phases, but lower in the IT and LR phases. Although CHB patients at the IT phase have very high levels of HBV DNA, their anti-HBc levels are comparable to those at the LR phase. Surprisingly, in the Chinese cohort, Wang et al. [4] (this issue) showed that CHB patients at the LR phase have anti-HBc levels similar to those at the IC phase, but higher than those at the IT and ENH phases. It remains unclear what causes this discrepancy. One plausible explanation is that they used a semi-quantitative assay rather than a genuine quantitative assay with the standardized international unit (IU). Collectively, the total antiHBc level may serve as a promising serological marker for HBV-induced liver disease. Compared to the ALT level, the anti-HBc level has less fluctuation in ENH patients. In addition, the anti-HBc level is complementary to current quantitative viral markers, including the HBsAg level and the HBV DNA level. The HBsAg level may reflect the transcription activity of HBV covalently closed circular DNA (cccDNA), whereas the anti-HBc level represents the host antiviral immune responses against the HBV core protein. The role of total anti-HBc level in predicting the long-term outcomes of CHB patients deserves further investigation.
Hepatitis B core-related antigen (HBcrAg), consisting of HBV core antigen (HBcAg), hepatitis B e antigen (HBeAg), and the 22-kDa precore protein (p22cr), has been suggested as an additional marker of CHB. HBcrAg has been shown to correlate other virological markers, including serum HBV DNA and intrahepatic cccDNA, so can serve a marker for disease activity and treatment response [17] . In addition, in a large European cohort predominantly infected with genotypes A and D, HBcrAg varied significantly in different phases of CHB. HBcrAg was high in the IT and IC phases, lower in the ENH phase, and lowest in the LR phase [18] . A large longitudinal cohort is required to further explore the role of HBcrAg as a marker for the long-term outcomes of CHB.
Considering the heterogeneous nature and clinical outcomes of CHB, precise definition of clinical phases of patients is the prerequisite to provide better medical care. A combination of existing and upcoming biomarkers may help to more accurately determine the clinical phases of chronic HBV infection. With the development of novel quantitative serological markers, we are confident in being able to refine the definition of each clinical phase. Moreover, we may further identify the subgroup of patients at risk. This has been exemplified by the story of HBsAg quantification, showing that a combination of HBV DNA level \2000 IU/mL, normal ALT level and HBsAg level \1000 IU/mL can define minimal-risk HBV carriers [9] .
In conclusion, the traditional natural history of CHB should be revisited with new quantitative serological or even immunological markers. The predictive value of combining these biomarkers in long-term clinical outcomes, including the risk of liver cirrhosis and HCC, should be scrutinized in a larger prospective cohort of patients with different HBV genotype infections from different parts of the world.
